Xcout Intel
Frontier Medicines Corp
Frontier Medicines, Corp. is a precision medicine company focusing on drug development with offices in locations including South San Francisco, California, and Boston.
Subscribe to see Frontier Medicines Corp’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Frontier Medicines Corp at a glance
Frontier Medicines Corp is a biotech company headquartered in United States, founded in 2018. It has raised at least $155.5M across the 2 funding rounds on record. Its most recent funding round raised $88.5M in June 2021. Xcout tracks 1 named person at Frontier Medicines Corp, including Chris Varma, Ph.D. (Co-founder, Chairman and CEO). Xcout recorded 8 job postings from Frontier Medicines Corp in the last 90 days.
Frontier Medicines Corp leadership
- Chris Varma, Ph.D.Co-founder, Chairman and CEO
Frontier Medicines Corp funding rounds
At least $155.5M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $88.5M | — | |
| — | $67M | 8 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Hiring at Frontier Medicines Corp
Xcout recorded 8 job postings from Frontier Medicines Corp in the last 90 days, from a hiring record Xcout has kept since July 2026.
The weekly hiring trend, the roles and locations behind it — see Frontier Medicines Corp's hiring signals →
Investors
Frontier Medicines Corp competitors
A few of Frontier Medicines Corp's closest competitors — see the full list of competitors and alternatives →
Gordian Biotechnology is a biotechnology research company headquartered in South San Francisco, California. The company focuses on curing age-related diseases through in vivo target discovery and functional genomics platforms.
Tessellate Bio is a biotechnology company that develops precision oncology medicines by exploring synthetic lethal interactions beyond homologous recombination deficiency. The company integrates biomarker discovery and companion diagnostics into its research programs to create first-in-class treatments for hard-to-treat cancers.
Fauna Bio is a biotechnology company headquartered in Berkeley, California. The company combines animal genomics and advanced data approaches to drive drug discovery and improve human health.
Relay Therapeutics, Inc. is a precision medicine company currently engaged in clinical trials. Its central mission involves revolutionizing the drug discovery process, with a particular focus on enhancing the creation of small molecule therapies for specific types of cancer and genetic conditions. The company's pipeline features several promising drug candidates: RLY-4008, an orally administered small molecule designed to inhibit fibroblast growth factor receptor 2 (FGFR2), which is undergoing its initial human trials for patients with advanced or metastatic solid tumors exhibiting FGFR2 alterations; RLY-2608, a leading program targeting mutant phosphoinositide 3 kinase alpha (PI3Ka); and RLY-1971, another oral small molecule, an inhibitor of SHP2 (protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2), currently in Phase 1 trials for individuals with advanced solid tumors. Relay Therapeutics has established strategic partnerships, including a collaboration with D. E. Shaw Research, LLC, which utilizes computational modeling to analyze protein motion for the identification and development of therapeutic compounds. Furthermore, an agreement with Genentech, Inc. supports the development and commercialization of RLY-1971. Founded in 2015 as Allostery, Inc., the company rebranded to Relay Therapeutics, Inc. in December of that year and maintains its headquarters in Cambridge, Massachusetts.
Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins. Among their key initiatives is an oral molecular glue degrader designed to target GSPT1, a specific translational termination factor and degron-containing protein, with the aim of treating Myc-driven cancers. The company's pipeline further includes programs for CDK2 in ovarian, uterine, and breast cancers, alongside NEK7 for addressing a spectrum of inflammatory conditions such as Crohn's disease, neurodegenerative ailments, diabetes, and liver disease. Moreover, VAV1 is being explored as a target for autoimmune disorders, and BCL11A, a protein holding significant therapeutic relevance, is under investigation for hemoglobinopathies. Founded in 2019, Monte Rosa Therapeutics, Inc. operates from its headquarters in Boston, Massachusetts.
Volastra Therapeutics, Inc. is a U.S. biotechnology company developing cancer medicines designed to prevent or treat metastasis, the spread of tumors to other parts of the body. It uses functional genomics and related technologies to discover therapeutic targets and serves the oncology and biopharmaceutical markets.
Get Frontier Medicines Corp's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Frontier Medicines Corp in Xcout Intel
- 1 named person with titles, LinkedIn and board committees
- 2 funding rounds with the investors in each, and who they co-invest with
- Weekly hiring history and the mix of roles behind it
- The full competitor set, tracking, exports and API access